First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer

PURPOSE: Endoxifen is a tamoxifen metabolite with potent antiestrogenic activity. PATIENTS AND METHODS: We performed a phase I study of oral Z-endoxifen to determine its toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clinical activity. Eligibility included endocrine-refractory, estr...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Oncol
Hoofdauteurs: Goetz, Matthew P., Suman, Vera J., Reid, Joel M., Northfelt, Don W., Mahr, Michael A., Ralya, Andrew T., Kuffel, Mary, Buhrow, Sarah A., Safgren, Stephanie L., McGovern, Renee M., Black, John, Dockter, Travis, Haddad, Tufia, Erlichman, Charles, Adjei, Alex A., Visscher, Dan, Chalmers, Zachary R., Frampton, Garrett, Kipp, Benjamin R., Liu, Minetta C., Hawse, John R., Doroshow, James H., Collins, Jerry M., Streicher, Howard, Ames, Matthew M., Ingle, James N.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Clinical Oncology 2017
Onderwerpen:
ORIGINAL REPORTS
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5648176/
https://ncbi.nlm.nih.gov/pubmed/28854070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.3246
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items